Sandoz Inaugurates BioInject – a new state-of-the-art biopharmaceutical manufacturing facility in Schaftenau, Austria
- Sandoz is investing over 150 million euro and creating 100 new highly qualified jobs
- The new BioInject facility will support Sandoz’s fast growing biosimilars business as well as other Novartis biologics
- State-of-the-art technology will strengthen Sandoz and Novartis in-house capabilities in drug product manufacturing
Schaftenau, September 17 2015 – Sandoz, the generics and biosimilars business of Novartis, today officially opened its new cutting-edge biomanufacturing facility called BioInject, at Schaftenau in the Tyrolean Alps in Austria. It is the result of over 150 million euro worth of investment with creation of 100 highly skilled jobs. In attendance at the event were Austrian dignitaries from national politics and the regional economy.
BioInject is a state-of-the-art facility that will be used to manufacture pre-filled syringes and devices for both Sandoz’s biosimilars and Novartis Pharma’s novel biologics. This new facility now means that 18,000 syringes can be filled per hour and 100 packaged per minute. It will play an important role in driving the next wave of biosimilars and novel biologics growth at Sandoz and Novartis Pharmaceuticals - growth that will ultimately help address unmet medical needs and broaden patient access to key biologics products.
Welcoming guests at the event, Carol Lynch, Global Head of Biopharmaceuticals and Oncology Injectables at Sandoz said “BioInject stands as a testament to both Sandoz’ technological leadership in biologics as well as the company’s commitment to further strengthening its global leadership in biosimilars.” BioInject will become a central part of Novartis’ biomanufacturing network which also includes facilities in Slovenia, Singapore and France.
Total investment of 2.2 billion euro in Austria since 1996
More than 2.2 billion euro has been invested in Austria since Novartis was first established in 1996. The group currently has over 4,600 employees at four sites and is therefore an important economic contributor particularly in the provinces of Tyrol, Upper Austria and Vienna.
Sandoz has an unwavering commitment to increasing patient access to high-quality, life-enhancing biosimilars. It is the pioneer and global market leaderi and currently markets three biosimilars in over 60 countries around the world. Sandoz recently became the first company to introduce a biosimilar in the United States, signaling the shift towards more competition and affordability envisaged by US lawmakers when they enacted Biologics Price Competition and Innovation Act (BPCIA). Sandoz has a leading pipeline with several biosimilars across the various stages of development, including five programs in Phase III clinical trials and filing preparation. As part of the Novartis Group, Sandoz is uniquely positioned to lead the biosimilars industry based on its experience and capabilities in development and manufacturing.
About biologics and biosimilars
Biologics are complex protein therapies which are produced in living organisms. Biologics have revolutionized modern medicine as they make it possible to treat complex diseases such as cancer and autoimmune diseases.
Biosimilars are approved biologics with comparable quality, safety and efficacy to the reference product. Biosimilars foster competition, leading to projected savings for healthcare systems, sustained innovation and increased patient access to treatment.
Sandoz, a division of Novartis, is a global leader in generic pharmaceuticals, driving sustainable access to high-quality healthcare. Sandoz employs more than 26,000 people worldwide and supplies a broad range of affordable, primarily off-patent products to patients and customers around the globe. The Sandoz global portfolio comprises approximately 1,100 molecules, which accounted for 2014 sales of USD 9.6 billion. Sandoz holds the global #1 position in biosimilars as well as in generic anti-infectives, ophthalmics and transplantation medicines. Nearly half of Sandoz’s portfolio is in differentiated products – products that are scientifically more difficult to develop and manufacture than standard generics. In addition to strong organic growth since consolidating its generics businesses under the Sandoz brand name in 2003, Sandoz has consistently driven growth in selected geographies and differentiated product areas through a series of targeted acquisitions.
For further information including images of the BioInject facility:
Sandoz Global Communications
+49 (0) 162 429 7971
iBased on IMS data covering all biosimilars approved in the combined markets of North America, Europe, Japan and Australia